Lysosome-derived biomarkers for predicting survival outcome in acute myeloid leukemia

Abstract Lysosomes have a tight connection to cancer and can eliminate cancer cells. The dismal prognosis of acute myeloid leukemia (AML) patients may thus be improved by a thorough examination of the function of lysosome-related genes (LRGs). By using a variety of machine learning methods including...

Full description

Saved in:
Bibliographic Details
Main Authors: Gongchang Li, Yangyang Miao, Fang Yuan, Weiran Zhang, Yali Wu, Liqiang Zhu
Format: Article
Language:English
Published: Springer 2025-08-01
Series:Discover Oncology
Subjects:
Online Access:https://doi.org/10.1007/s12672-025-03302-8
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849235008873562112
author Gongchang Li
Yangyang Miao
Fang Yuan
Weiran Zhang
Yali Wu
Liqiang Zhu
author_facet Gongchang Li
Yangyang Miao
Fang Yuan
Weiran Zhang
Yali Wu
Liqiang Zhu
author_sort Gongchang Li
collection DOAJ
description Abstract Lysosomes have a tight connection to cancer and can eliminate cancer cells. The dismal prognosis of acute myeloid leukemia (AML) patients may thus be improved by a thorough examination of the function of lysosome-related genes (LRGs). By using a variety of machine learning methods including random forest approach, LASSO-COX regression, and extreme gradient boosting (XGBoost), we create a prognostic six-LRGs-related signature (HPS1, BCAN, SLC2A8, DOC2A, CHMP4C, and SLC29A3), which categorized AML patients into two groups with significant survival and tumor microenvironment (TME) differences. Data from the ICGC and TARGET cohorts were used as test cohorts for the validation of the prognostic LRGs-related signature. We also discovered that chemotherapeutic susceptibility was connected to the LRGs-related signature. Finally, we evaluated gene expression levels in the LRGs-related signature between normal and AML samples and confirmed the elevation of CHMP4C expression in 90 clinical samples. In summary, a six-LRGs-related signature was developed to predict the prognosis of AML patients, and more research is necessary to determine whether this signature has therapeutic promise as an anti-AML target.
format Article
id doaj-art-6356b605d9a842aa8c327dcb2d43e4cd
institution Kabale University
issn 2730-6011
language English
publishDate 2025-08-01
publisher Springer
record_format Article
series Discover Oncology
spelling doaj-art-6356b605d9a842aa8c327dcb2d43e4cd2025-08-20T04:02:56ZengSpringerDiscover Oncology2730-60112025-08-0116111210.1007/s12672-025-03302-8Lysosome-derived biomarkers for predicting survival outcome in acute myeloid leukemiaGongchang Li0Yangyang Miao1Fang Yuan2Weiran Zhang3Yali Wu4Liqiang Zhu5The Second Affiliated Hospital of Zhengzhou UniversityZhengzhou Central Hospital Afflicted of Zhengzhou UniversityThe Second Affiliated Hospital of Zhengzhou UniversityThe Second Affiliated Hospital of Zhengzhou UniversityThe Second Affiliated Hospital of Zhengzhou UniversityThe Second Affiliated Hospital of Zhengzhou UniversityAbstract Lysosomes have a tight connection to cancer and can eliminate cancer cells. The dismal prognosis of acute myeloid leukemia (AML) patients may thus be improved by a thorough examination of the function of lysosome-related genes (LRGs). By using a variety of machine learning methods including random forest approach, LASSO-COX regression, and extreme gradient boosting (XGBoost), we create a prognostic six-LRGs-related signature (HPS1, BCAN, SLC2A8, DOC2A, CHMP4C, and SLC29A3), which categorized AML patients into two groups with significant survival and tumor microenvironment (TME) differences. Data from the ICGC and TARGET cohorts were used as test cohorts for the validation of the prognostic LRGs-related signature. We also discovered that chemotherapeutic susceptibility was connected to the LRGs-related signature. Finally, we evaluated gene expression levels in the LRGs-related signature between normal and AML samples and confirmed the elevation of CHMP4C expression in 90 clinical samples. In summary, a six-LRGs-related signature was developed to predict the prognosis of AML patients, and more research is necessary to determine whether this signature has therapeutic promise as an anti-AML target.https://doi.org/10.1007/s12672-025-03302-8LysosomeAMLMachine learningPrognosisCHMP4C
spellingShingle Gongchang Li
Yangyang Miao
Fang Yuan
Weiran Zhang
Yali Wu
Liqiang Zhu
Lysosome-derived biomarkers for predicting survival outcome in acute myeloid leukemia
Discover Oncology
Lysosome
AML
Machine learning
Prognosis
CHMP4C
title Lysosome-derived biomarkers for predicting survival outcome in acute myeloid leukemia
title_full Lysosome-derived biomarkers for predicting survival outcome in acute myeloid leukemia
title_fullStr Lysosome-derived biomarkers for predicting survival outcome in acute myeloid leukemia
title_full_unstemmed Lysosome-derived biomarkers for predicting survival outcome in acute myeloid leukemia
title_short Lysosome-derived biomarkers for predicting survival outcome in acute myeloid leukemia
title_sort lysosome derived biomarkers for predicting survival outcome in acute myeloid leukemia
topic Lysosome
AML
Machine learning
Prognosis
CHMP4C
url https://doi.org/10.1007/s12672-025-03302-8
work_keys_str_mv AT gongchangli lysosomederivedbiomarkersforpredictingsurvivaloutcomeinacutemyeloidleukemia
AT yangyangmiao lysosomederivedbiomarkersforpredictingsurvivaloutcomeinacutemyeloidleukemia
AT fangyuan lysosomederivedbiomarkersforpredictingsurvivaloutcomeinacutemyeloidleukemia
AT weiranzhang lysosomederivedbiomarkersforpredictingsurvivaloutcomeinacutemyeloidleukemia
AT yaliwu lysosomederivedbiomarkersforpredictingsurvivaloutcomeinacutemyeloidleukemia
AT liqiangzhu lysosomederivedbiomarkersforpredictingsurvivaloutcomeinacutemyeloidleukemia